the use of different coding dictionaries and different timewindow definitions for statin exposure might explain the different results. van Staa argued that varying definitions of follow-up between users and non-users could have created an imbalance in the matching of fracture cases in the study by Meier et al. 3, 7 None of these hypotheses have been formally tested. Furthermore, randomized controlled clinical trials (RCTs) have provided little evidence for statins as anti-osteoporotic agents ( Figure 1 ). [8] [9] [10] [11] The objective of this study was to examine whether different matching procedures, time-window definitions, and exclusion criteria might explain the discrepant results of the two case-control studies by Meier et al. and van Staa et al. Table 1 lists the major differences between both study designs, including those that this paper will evaluate as the reason for the different results.
Methods
We replicated the study design of Meier et 
'SP' case-control dataset
The SP case-control dataset was created in three defined cohorts of patients. 2 The first cohort included all patients who received at least one prescription for a statin (i.e. atorvastatin, cerivastatin, fluvastatin, pravastatin, or simvastatin), a fibrate (i.e. bezafibrate, ciprofibrate, clofibrate, fenofibrate, or gemfibrozil), or a lipid-lowering drug other than statins or fibrates (i.e. colestipol hydrochloride, cholestyramine, acipimox, or nicotinic acid). The second cohort consisted of all people with a diagnosis of hyperlipidaemia and the third cohort consisted of a random sample of 2 50 000 people who received neither a diagnosis of hyperlipidaemia nor a prescription for a lipid-lowering drug at any time. These patient numbers are proportionally similar to those analysed by Meier et al. 2 Start of data collection was defined as the date of enrolment of a patient in a practice or the date of enrolment of a practice in GPRD, whichever came later. The start of follow-up for this study was defined as the date of the first prescription of a lipid-lowering drug (cohort 1) or as the start of data collection (cohort 2 and 3). Within these three cohorts, all patients with a first occurrence of a fracture were identified. The fractures were restricted to those of the femur/hip, humerus, hand, wrist, or lower arm, vertebrae, clavicle, foot, or malleolus or an unspecified location, similar to those selected by Meier et al.
2
The date of the fracture was taken as the index date. From the three cohorts, up to six control patients were randomly selected for each case. Cases and controls could be selected from different cohorts. They were matched by year of birth, sex, practice, and the year of start of follow-up using the incidencedensity sampling technique. Controls had to be alive and enrolled in GPRD at the index date. If no controls of similar age could be found, the age band used for matching was expanded stepwise up to a maximum of 5 years. 2 If no control within the 5 year age band could be identified, the case was matched to a control with similar matching parameters except for the practice criterion. Control patients had the same index date as their matched case.
'EP' case-control dataset
The EP case-control dataset was created in the total GPRD population of patients aged 50 years or older, similar to the methodology used by van Staa and co-workers. 3, 4 Cases were permanently registered patients with a first-ever fracture after the start of data collection. Each case was matched to one control patient (patients without a history of any type of fracture) by year of birth, calendar time, sex, and general practice using the incidence sampling technique.
Exposure assessment
Users of lipid-lowering agents were classified according to single or mixed use before the index date of statins, fibrates, or other lipid-lowering drugs, according to the classification in the original SP analysis. 2 As the time-window for exposure to lipid-lowering drugs was defined differently in the two original studies, two definitions were used. In the first definition (similar to that used by Meier et al.) , current users were patients who were prescribed a lipid-lowering drug in the 30 days or less before the index date. The second exposure definition (similar to that used by van Staa and co-workers) defined current users as patients who were prescribed a lipid-lowering drug in the 6 months or less before the index date. Exposure duration was assessed by counting the number of statin prescriptions, as used in the original SP study design. 2 Time since first statin use was determined by calculating the period between index date and first prescription.
Statistical analysis
Crude ORs of fracture in statin users compared with neverusers and 95% confidence intervals (CI) were estimated using conditional logistic regression. A history of diabetes mellitus, rheumatoid arthritis, congestive heart failure, seizures, thalassaemia, sickle cell disease, pernicious anaemia, dementia, psychotic disorder, stroke, and chronic obstructive pulmonary disease and a history of hyperthyroidism or falls 1 year before the index date were considered as potential confounding variables. Prescribing in the 6 months prior to index date for anticonvulsants, methotrexate, hormone replacement therapy (HRT), thiazide diuretics, beta-blockers, anxiolytics/ hypnotics, antipsychotics, antidepressants, anti-Parkinson drugs, systemic and inhaled corticosteroids, bronchodilators, and a minimum of 3 prescriptions of non-steroidal antiinflammatory drugs (NSAIDs) were also included in the regression analysis. The last recorded smoking status and body mass index (BMI) before the index date were also included (some practices do not enter these data since it is not part of required data collection). Adjustment for these variables is referred to as the 'fully adjusted model'. In order to replicate the adjustments in the original analysis by Meier et al., 2 the number of general practitioner (GP) visits before the index date was also calculated. Final adjusted models were fitted using backward elimination. The Mantel-Haenszel estimator of combined ORs of randomized clinical trials in Figure 1 was calculated according to the method described by Hauck. 12 Spline regression lines were calculated using the GPLOT procedure of SAS version 8.2 (SAS Institute Inc., Cary, NC, USA). Table 2 shows baseline characteristics in the two case-control datasets. In the SP case-control dataset, only 37% of the cases had been matched to controls by year of birth, while this was achieved for 99% of patients in the EP case-control dataset. The risks of fracture among those who had received one or more statin prescriptions in the 6 months before were generally lower with the SP case-control dataset, compared with the EP case-control dataset (Table 3) The use of shorter time-windows for measuring current statin use reduced the ORs for fracture. The fully adjusted OR for hip fracture was 0.49 (95% CI 0.24-1.00) in the EP casecontrol dataset when defining exposure on the basis of statin prescribing in the 1 week before the index date, compared with an OR of 0.78 (95% CI 0.60-1.02) when using a time-window of 2 years ( Figure 2 ). In both study designs, 60% of the case patients and 65% of the control patients who were exposed to statins in the 6 months before the index date were also exposed to statins in the 30 days before the index date. Table 4 shows the effects of changes in matching procedures and patient selection on the risk of hip fracture in statin users.
Matching by exact year of birth, instead of using a 5 year age band, decreased the differences between the two designs and moved ORs towards 1. Exclusion of patients at high risk of fracture had different effects on ORs: the magnitude of the effect in the SP dataset [adjusted OR for hip fracture of 0.44 (95% CI 0.24-0.79)] increased whereas the opposite was the case in the EP dataset [OR 0.67 (95% CI 0.46-0.98)]. In the original SP case-control dataset, start of follow-up was defined differently between users and non-users of statins and, consequently, the amount of follow-up time used to determine high-risk status differed between users and non-users of statins (means of 1.7 and 4 years, respectively). The inclusion of femur fractures with unspecified location of fracture, the exclusion of patients who were 90 years and older, or matching by duration of follow-up in the SP case-control dataset did not substantially change results. Figure 3 shows the association between the number of statin prescriptions before the index date and the adjusted OR for hip fracture in both study designs. Among current users, the risk of hip fracture was reduced after only one statin prescription (30 days of treatment) and remained stable with increasing numbers of prescriptions.
Discussion
We examined methodological reasons for the discrepant results of two previous case-control studies that examined the association between use of statins and risk of fracture in the same database. 2, 3 We found that the age-band used for matching cases and controls, the selection of potential confounders, the exclusion of high-risk patients, and different definitions for exposure time-windows led to differences in results between the SP and the EP case-control study designs. We found that results changed substantively with the choice of the exposure time-window. The two case-control studies applied different time-windows for exposure: Meier assessed the statin prescribing in the 30 days prior to the index date, while van Staa used a 6 month period. 2, 3 The exposure time-window should cover the time-period during which the drug can cause or prevent the outcome, which is related to the lag-time of effect after start of treatment and cessation of effect after treatment discontinuation. The length and timing of this exposure time-window can influence the estimates of exposure risks. 13, 14 It seems unlikely that statins' effect on the bone occur within 30 days of start of use. In vitro, statins protect bone through a mechanism similar to aminobisphosphonates.
15,16
Two large randomized controlled clinical trials reported reductions in hip fracture risk only after 6-12 months of bisphosphonate use. 17, 18 This suggests that a longer timewindow is appropriate in the evaluation of the effects of statins on the bone. Both studies matched fracture cases to controls by age and used a matching procedure that expanded the difference in age in a stepwise manner, if no control was found. We found that the SP and EP case-control studies yielded different results when using the broader matching for age, but this difference disappeared when matching by year of birth. The SP casecontrol dataset based on the broad age matching criteria included hip fracture cases that were on average 2 years older than their matched controls in the SP dataset. In contrast there was no difference in age between cases and controls in the EP dataset. The SP case-control study obtained controls from three selected cohorts, which included a much smaller number of patients compared with the total GPRD population used in the EP case-control study. Age is a strong risk factor for fracture risk, and residual confounding may, thus, explain part of the risk reduction observed in the SP case-control study.
In laboratory studies, Mundy et al. found positive effects of statins on the expression of bone morphogenetic protein 2 (BMP-2) and bone growth. 1 Following this, several epidemiological studies were conducted. Pooling the results of these observational studies, Bauer et al. reported a summary OR for hip fracture risk in statin users of 0.43 (95% CI 0.25-0.75). 19 However, the pooling of the results of randomized clinical trials did not provide strong evidence for a protective effect of statins for any type of fracture ( Figure 1 ). Our study included the largest number of statin users compared with previous research, and we were able to conduct a detailed analysis of the association between duration of statin use and risk of fracture. A decreased risk of hip fracture was found already after one statin prescription and there was no relationship between duration of statin use and size of fracture risk reduction. It seems unlikely that this reduction in risk within 30 days of statin treatment is caused by pharmacological effects of statins. Although Mundy reported an increased bone formation in rodents already after 5 weeks of simvastatin administration, 1 this seems implausible in humans given the limited number of bone remodelling sites. The reduced fracture risk observed in this study might, thus, be due to unknown confounders. It might be related to confounding by socioeconomic status and the 'healthy drug user' effect, biases that have been proposed as an explanation for different results of clinical trials and observational research in the study of HRT and coronary heart disease. [20] [21] [22] [23] Although few studies have examined the association between socioeconomic status and hip fracture risk, a large population-based case-control study suggests that low socioeconomic status is associated with increased risk of hip fracture. 24 In addition, in a large cohort study, lower socioeconomic status appeared to be inversely associated with statin use. 25 Healthy user bias is likely to have occurred because long-term statin users tend to be healthier and physically more active than non-users. 26 Unfortunately, these hypotheses cannot be tested directly in the GPRD, as information on socioeconomic status or 'healthy drug users' was not available in GPRD at the time of data collection. However, as of 2006, the GPRD will be using a trusted third party to enable record linkage to other NHS datasets. Such linkage is planned for small-area deprivation indices. Inadequate adjustment for socioeconomic status and healthy user bias are likely explanations for the discrepant findings between observational studies and randomized controlled trials in the study of statin use and fracture risk, but this should be examined in future studies. The objective of this study was not to exactly replicate the results of the two studies but to test various hypotheses that could explain the discrepant results. For this purpose, we used a single dataset with similar definitions for drug exposures and diagnoses. Our study designs were not identical to those employed by Meier and van Staa, as we did not have access to all computer programs and coding dictionaries. Moreover, restoring the original datasets using the same date ranges was virtually impossible. After July 1999, several general practices have contributed additional data from the period 1987 through 1999, which were not available at the time Meier and van Staa did their analyses. Thus, our study was conducted in a larger and more recent GPRD dataset. As the use of statins has increased dramatically in recent years, the characteristics of statin users may have changed over time. Another limitation was that there was incomplete recording for BMI and smoking, as these data are not part of compulsory data collection in GPRD.
Our results have important methodological implications. Residual confounding by a matching variable may occur when a case-control study is nested within a relatively small cohort, especially when multiple matching variables are used. In case-control studies of drug use and fracture risk, broad matching criteria for age should be avoided and the selection of the time-window for exposure should be carefully considered. 
